Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients

Απλή σελίδα τεκμηρίου
dc.contributor.authorPavlidis, N. A.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorKalef-Ezra, J.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorSeferiadis, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T18:52:02Z
dc.date.available2015-11-24T18:52:02Z
dc.identifier.issn0393-6155-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18346
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAscites/metabolismen
dc.subjectCA-125 Antigen/blooden
dc.subjectCarcinoma/blood/drug therapy/*immunology/mortalityen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Proteins/*blooden
dc.subjectOvarian Neoplasms/blood/drug therapy/*immunology/mortalityen
dc.subjectPrognosisen
dc.subjectReceptors, Interleukin-2/*analysisen
dc.subjectRetrospective Studiesen
dc.subjectSolubilityen
dc.subjectTreatment Outcomeen
dc.subjectTumor Markers, Biological/*blooden
dc.titleSerum soluble interleukin-2 receptors in epithelial ovarian cancer patientsen
heal.abstractThe levels of soluble interleukin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-R2 was increased in 37 patients (71.2%). Comparison of these levels to those of normal controls showed a highly statistically significant difference (p < 0.001). Serum sIL-R2 levels were not related to histology, clinical stage or the presence of ascites (p = 0.58, p = 0.32 and p = 0.67, respectively), nor did they follow disease activity or response to chemotherapy. However, patients with higher pretreatment sIL-2R levels (more than 1200 U/ml) were found to have a longer survival (p < 0.02), possibly explained by the presence of activated lymphocytes and a better immune surveillance. We conclude that the serum level of sIL-R2: a) is elevated in ovarian cancer patients, b) has no relationship with histological subtypes, tumor burden or the presence of ascites, c) cannot serve as a valuable tumor marker for the monitoring of patient treatment, and d) has a prognostic value for survival.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/7561242-
heal.journalNameInt J Biol Markersen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1995-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ